David Boyer, MD
Enriched profileSenior Partner, Retina-Vitreous Associates Medical Group; Adjunct Clinical Professor of Ophthalmology, USC Keck School of Medicine · Retina-Vitreous Associates Medical Group
David Boyer is Senior Partner, Retina-Vitreous Associates Medical Group; Adjunct Clinical Professor of Ophthalmology, USC Keck School of Medicine at Retina-Vitreous Associates Medical Group. OpenAlex indexes 335 publications with 27,669 citations (h-index 66); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
David S. Boyer, MD, is Senior Partner, Retina-Vitreous Associates Medical Group. The public record shows 335 publications with 27,669 citations (h-index 66), centered on Retinal Diseases and Treatments, Retinal and Optic Conditions, Retinal Imaging and Analysis. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 38 companies, 2 NIH-funded awards (1985–2026).
- Most recent indexed publication: 2026 · Clinical ophthalmology (Auckland, N.Z.)
- Top research focus: Retinal Diseases and Treatments
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 38 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 145.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema
Sponsor: Retina-Vitreous Associates Medical Group
- A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Sponsor: KalVista Pharmaceuticals, Ltd.
- Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
Sponsor: Valley Retina Institute
Industry payments
Updated 13 Oct 2026
38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20255 payments
- Boehringer Ingelheim International GmbHProgram year20253 payments
- Amgen Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
79.4%Antineovascularisation agents76.7%Faricimab-svoa100%Part B, office-administered≥176 patientsVascular Endothelial Growth Factor Inhibitor0.9%Ranibizumab100%Part B, office-administered≥38 patients+ 9 more classes in this area
Cancer & immunology
20.1%Complement Inhibitor17.2%Pegcetacoplan100%Part B, office-administered≥111 patientsVascular Endothelial Growth Factor Inhibitor2.9%Aflibercept95%Bevacizumab5%Part B, office-administered≥223 patients+ 1 more class in this area
Musculoskeletal
0.2%Cyclooxygenase Inhibitor0.2%Ketorolac Tromethamine100%Part D≥71 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
2 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- Structure determination of amyloid oligomers and amyloid-TREM2 complexes
University of California Los Angeles
FY2026$126,063K99AG095272
Congress activity
Updated 13 Oct 2026
1 congress contribution (2023) across ADA per OpenAlex. The most recent:
- 25-LB: Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy
ADA Scientific Sessions
ADA2023Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.
Clinical ophthalmology (Auckland, N.Z.)
Article2026 - Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.
Eye (London, England)
Article2026 - Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema.
Journal of vitreoretinal diseases
Article2024 - Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.
Journal of vitreoretinal diseases
Article2023
Most-cited works
by citation count (OpenAlex)- 01Ranibizumab for Neovascular Age-Related Macular Degeneration5,873 citations2006
- 02Ranibizumab for Diabetic Macular Edema1,604 citations2012
- 03
- 04
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/david-boyer-md-855a639
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
retinapodcast.com/episodes/2025/1/20/episode-455-photobiomodulation-discussion-with-dr-david-boyer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →retinapodcast.com ↗ - Other
touchophthalmology.com/retina-vitreous/conference-hub/david-boyer-arvo-2023-retinitis-pigmentosa-and-the-unmet-needs-in-its-treatment
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchophthalmology.com ↗ - Other
healio.com/cme/mededtalks/ophthalmology/20241022/7-the-retina-radar-with-dr-arshad-khanani/overview
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile: David Boyer, MD - Retina-Vitreous Associates Medical Group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗
- BS
University of Illinois at Urbana-Champaign
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - MD
Chicago Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - Retinal surgery fellowship
Wills Eye Hospital, Philadelphia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗
- Senior Partner
Retina-Vitreous Associates Medical Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →laretina.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wwlifetimeachievement.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →laretina.com ↗
- American Academy of Ophthalmology Achievement
Senior Achievement, Secretariat, and Lifetime Achievement Awards
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - American Society of Retina Specialists Honor
Senior Honor, and Founders Awards
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laretina.com ↗ - Jules Stein Living Tribute Award
Retinitis Pigmentosa International
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wwlifetimeachievement.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →laretina.com ↗
Secondary affiliations
appointments beyond the home institution- Adjunct Clinical Professor of Ophthalmology
University of Southern California/Keck School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emedevents.com ↗ - Scientific Advisory Board
Clearside Biomedical, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ir.clearsidebio.com ↗ - Team/advisor
Opus Genetics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →opusgtx.com ↗ - Advisor
Amydis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amydis.com ↗ - Team
4D Molecular Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →4dmoleculartherapeutics.com ↗ - Team member
Ashvattha Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avttx.com ↗ - Scientific & Clinical Advisor
Aviceda Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Advisor
EyePoint Pharmaceuticals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eyepointpharma.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
- Regular contributing author
Modern Retina
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →modernretina.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York